Merck & CompanyvsVor Biopharma

MRK and VOR stock compared: price, dividend, valuation and results, from SEC filings.

MRK

Merck & Company, Inc.

$133.72

Value $331B

+0.69%
MRK's page

VOR

Vor Biopharma Inc.

$19.19

Value $1.2B

+3.62%
VOR's page

Merck & Company (MRK) has a market value of $331B and Vor Biopharma (VOR) $1.2B. Over the last year, with dividends, MRK moved +44.8% and VOR +145.4%. Dividend yield: MRK 2.54%, VOR none.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    MRK$331B

    VOR$1.2B

    MRK is 280 times VOR

  • Revenue, 12 months

    MRK$67.4B

    VOR–

  • Net income, 12 months

    MRK$2.5B

    VOR$1.4B

    MRK is 1.8 times VOR

  • Operating margin

    MRK–

    VOR–

  • ROIC

    MRK3.9%

    VOR–

  • P/E

    MRK134.8

    VOR–

  • Dividend yield

    MRK2.5%

    VOR0.0%

    2.5 points apart

  • 5-year return

    MRK+93.0%

    VOR-92.9%

    185.9 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

MRK+93.0%

VOR-92.9%

010020020222023202420252026
Returns by period
PeriodMRKWith dividendsVORWith dividends
1 year since November 19, 2025+44.8%Price +40.7%+145.4%Price +145.4%
3 years since November 20, 2023+42.7%+12.6% a yearPrice +30.2%-43.2%-17.2% a yearPrice -43.2%
5 years since November 19, 2021+93.0%+14.1% a yearPrice +65.7%-92.9%-41.1% a yearPrice -92.9%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

MRKMerck & CompanyVORVor Biopharma

Valuation

MRKVOR
Valuation
Price$133.72$19.19
Market value$331B$1.2B
Enterprise value (EV)$375B$697M
P/E134.8–
P/E, 5-year median14.8–
P/B7.4–
EV/EBIT78.7–
Free cash flow yield4.5%–

Results and growth

MRKVOR
Results and growth
Revenue, 12 months$67.4B–
Net income, 12 months$2.5B$1.4B
Free cash flow, 12 months$14.7B-$120M
Earnings per share, 12 months$0.98$27.71
Revenue growth, year on year1.3%–
Revenue growth a year, past+9.4%over 5 years–
EPS growth a year, past+21.2%over 5 years–

Margins and returns on capital

MRKVOR
Margins and returns on capital
Gross margin71.8%–
Operating margin––
Net margin3.6%–
ROIC3.9%–
ROE5.2%–

Balance sheet

MRKVOR
Balance sheet
Cash$9.7B$482M
Total debt$53.8B$2.8M
Net debt / EBITDA5.7–
Interest cover2.4×–

Dividends and buybacks

MRKVOR
Dividends and buybacks
Dividend yield2.5%–
Dividend per share, 12 months$3.40–
Dividend growth a year, past+5.8%over 5 years–
Buyback yield1.5%–
Shareholder yield4.1%–

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: MRK or VOR

Didn't find what you were looking for?

Ask us
Which is bigger, Merck & Company or Vor Biopharma?

By market value, Merck & Company ($331B) is about 280.4 times Vor Biopharma ($1.2B), at today's prices.

How did MRK and VOR stock do over the last 5 years?

Since November 19, 2021, MRK's price moved +65.7% and VOR's -92.9%. With dividends: MRK +93.0% (+14.1% a year), VOR -92.9% (-41.1% a year). Past returns do not predict future ones.

Which pays the higher dividend, MRK or VOR?

The dividend yield at today's price is 2.54% for Merck & Company and none for Vor Biopharma. Over the last twelve months they paid $3.40 and – per share.

Which is the better investment, Merck & Company or Vor Biopharma?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.